Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BASi Announces Expansion into Surgical Models and Medical Devices with Agreement to Purchase Pre-Clinical Research Services

11/08/2019 | 03:00pm EDT

WEST LAFAYETTE, Ind., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), a leading provider of nonclinical and analytical contract research services, today announced that the Company has entered into an agreement to purchase substantially all of the assets of Pre-Clinical Research Services, Inc. (“PCRS”), a premier provider of surgical and medical device contract research services.

“We have great respect for the people and services provided by PCRS, and believe the current facilities in Ft. Collins, Colorado, will be an excellent location for future growth,” said Bob Leasure, BASi’s President and Chief Executive Officer. “Our Companies have worked together for several years on multiple projects. Becoming one with PCRS will allow us to provide broader services in more areas of research and development than ever before. The combination will further expand our toxicology business and brings the ability to provide surgical services for pharmaceutical and medical device clients. We believe this addition is perfectly aligned with our strategy of being right-sized; small enough to be flexible and responsive, and comprehensive enough to have meaningful impact on our clients’ product development needs. The facilities and leadership team at PCRS are an excellent complement to our already strong team, and we look forward to working with them to continue to build this team and expand the business in the future.”

Dr. Donald Maul, founder and president of PCRS, added, “At PCRS we have catered to clients that were focused on medical devices and surgical models—it has become our brand. Very often we needed to rely on outside collaborators to fully support a project. By coming together with BASi, we will become much more comprehensive and have the ability to provide bioanalytical, histology, pathology, and pharmacokinetic evaluations. The combination will also afford our clients the ability to work in non-human primate models. Formalizing our partnership with BASi makes it easier for our clients to do more sophisticated projects with a provider that is dedicated to providing quality service.” 

By combining BASi and PCRS, our clients will have the ability to work with one provider having expertise in a broad range of scientific disciplines, including:

  • Pharmacology
  • Toxicology
  • Drug Metabolism
  • Pharmacokinetics
  • Bioanalysis
  • Intravascular Device and Structural Heart Models
  • Surgical and Medical Devices
  • Scientific and Regulatory Consulting

The transaction is subject to customary closing processes and is anticipated to close within calendar 2019. A Current Report on Form 8-K containing further details regarding the contemplated transaction has been filed by BASi and is available on the U.S. Securities and Exchange Commission’s EDGAR website.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit www.BASinc.com for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof and various market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.


Company Contact:
Jill C. Blumhoff
Chief Financial Officer
Phone: 765.497.8381

Primary Logo

ę GlobeNewswire 2019
All news about INOTIV, INC.
09/23INOTIV MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Whether the Me..
09/23INOTIV : Prices Upsized $125 Million Senior Notes Offering to Fund Envigo Acquisition
09/22Inotiv, Inc. Prices Upsized $125 Million Convertible Senior Notes Offering
09/22Top Midday Decliners
09/21INOTIV : Announces Proposed Convertible Senior Notes Offering (Form 8-K)
09/21INOTIV, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (..
09/21INOTIV : to Raise $110 Million via Senior Notes Offering to Fund Envigo Acquisition, Share..
09/21INOTIV : Announces Proposed Convertible Senior Notes Offering
09/21Health Care Stocks Holding Onto Gains in Late Trade
09/21ORIC PHARMACEUTICALS : Health Care Stocks Mostly Higher in Afternoon Trade
More news
Analyst Recommendations on INOTIV, INC.
More recommendations
Financials (USD)
Sales 2021 84,0 M - -
Net income 2021 -5,14 M - -
Net Debt 2021 - - -
P/E ratio 2021 -89,1x
Yield 2021 -
Capitalization 547 M 547 M -
Capi. / Sales 2021 6,51x
Capi. / Sales 2022 4,22x
Nbr of Employees 409
Free-Float 62,5%
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 34,32 $
Average target price 64,50 $
Spread / Average Target 87,9%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.0.00%547
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353